Document Type
Journal Article
Publication Title
Bone
Volume
188
PubMed ID
39153587
Publisher
Elsevier
School
Nutrition and Health Innovation Research Institute /School of Medical and Health Sciences
Funders
National Heart Foundation (107194) / Edith Cowan University / National Health and Medical Research Council
Grant Number
NHMRC Number : GNT1157930
Abstract
Understanding the mechanisms involved in whole body glucose regulation is key for the discovery of new treatments for type 2 diabetes (T2D). Historically, glucose regulation was largely focused on responses to insulin and glucagon. Impacts of incretin-based therapies, and importance of muscle mass, are also highly relevant. Recently, bone was recognized as an endocrine organ, with several bone proteins, known as osteokines, implicated in glucose metabolism through their effects on the liver, skeletal muscle, and adipose tissue. Research efforts mostly focused on osteocalcin (OC) as a leading example. This review will provide an overview on this role of bone by discussing bone turnover markers (BTMs), the receptor activator of nuclear factor kB ligand (RANKL), osteoprotegerin (OPG), sclerostin (SCL) and lipocalin 2 (LCN2), with a focus on OC. Since 2007, some, but not all, research using mostly OC genetically modified animal models suggested undercarboxylated (uc) OC acts as a hormone involved in energy metabolism. Most data generated from in vivo, ex vivo and in vitro models, indicate that exogenous ucOC administration improves whole-body and skeletal muscle glucose metabolism. Although data in humans are generally supportive, findings are often discordant likely due to methodological differences and observational nature of that research. Overall, evidence supports the concept that bone-derived factors are involved in energy metabolism, some having beneficial effects (ucOC, OPG) others negative (RANKL, SCL), with the role of some (LCN2, other BTMs) remaining unclear. Whether the effect of osteokines on glucose regulation is clinically significant and of therapeutic value for people with insulin resistance and T2D remains to be confirmed.
DOI
10.1016/j.bone.2024.117238
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Comments
Smith, C., Lin, X., Parker, L., Yeap, B. B., Hayes, A., & Levinger, I. (2024). The role of bone in energy metabolism: A focus on osteocalcin. Bone, 188. https://doi.org/10.1016/j.bone.2024.117238